Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PILLAR: Implementation of Cabotegravir PrEP in MSM and Transgender Men
NCT05374525Phase 4Completed
- Sponsor
- ViiV Healthcare
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cabotegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Mean Feasibility of Intervention Measure Score Assessed for Staff Study Participants at Month 12. Started May 2022; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05374525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374525.